TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Oct 05, 2022 19:55 JST
Source:
AIM Vaccine Co., Ltd.
AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 per H Share
To Commence Trading on the Main Board of the Hong Kong Stock Exchange on 6 October 2022
HONG KONG, Oct 05, 2022 - (ACN Newswire) - AIM Vaccine Co., Ltd. ("AIM Vaccine" or the "Company", together with its subsidiaries, the "Group", stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), today announced the allotment results of its Global Offering. The Offer Price is HK$16.16 per H share. Dealings in the H shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") are expected to commence on 6 October 2022 (Thursday) in board lot of 200 H shares each.
The H shares initially offered under the International Offering were over-subscribed. The net proceeds from the Global Offering are intended for advancing R&D of vaccine candidates and continuing to enrich vaccine pipeline, funding the capital expenditure on the construction of new production facilities for new vaccine products, and investing in sales and marketing activities. The Company said, through one decade of organic growth and external resource integration, AIM Vaccine has become a major player in the Chinese vaccine industry. The official listing on the Hong Kong Stock Exchange marks an important milestone in the history of the development of AIM Vaccine, opening a new chapter for the Company's development. The successful listing shows the trust and support of global investors for the Company's business development, and lays a firm ground for the Company's long-term growth. Looking forward, AIM Vaccine will carry on accelerating the R&D and commercialization process of the pipeline of vaccine candidates, and become a world-class vaccine company, thereby continuing to create greater value for shareholders.
Source: AIM Vaccine Co., Ltd.
Sectors: BioTech, Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
AIM Vaccine, a Major Player in the Chinese Vaccine Industry, Successfully Listed on the Main Board of SEHK
October 06 2022 19:16 JST
AIM Vaccine Announces Proposed Listing on the Main Board of SEHK
September 23 2022 17:06 JST
Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance
January 12 2022 10:26 JST
More Press release >>
Latest Press Release
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony in Shimonoseki for Training Ship WAKASHIO MARU Built for National Institute of Technology, Toyama College
Oct 24, 2025 00:29 JST
Mazda and Nippon Steel Strengthen Collaboration
Oct 23, 2025 23:57 JST
Immersive Museum "THE MOVEUM YOKOHAMA by TOYOTA GROUP" to Open on December 20, 2025
Oct 23, 2025 23:27 JST
PacificLight Appoints a Consortium of Mitsubishi Power and Jurong Engineering Limited to build 670 MW CCGT Power Plant in Singapore
Oct 23, 2025 23:12 JST
NEC and the Cote d'Ivoire Ministry of Agriculture enhance agricultural efficiency through digital technology
Oct 22, 2025 20:55 JST
Fujitsu and Kawasaki Frontale sign global Sports for Nature Framework in Japan first
Oct 22, 2025 18:16 JST
Olympus Launches New Surgical Energy Device for Hemostatic Cutting and Vessel Sealing
Oct 21, 2025 23:00 JST
MHI Thermal Systems to Launch New 2026 Models of the S Series High-Capacity Residential-Use Air-Conditioners for the Japanese Market
Oct 21, 2025 22:10 JST
New Land Cruiser "FJ" Makes World Premiere
Oct 21, 2025 21:29 JST
Sharp Initiates Collaboration with ARAV Corporation for Remote Control Solutions of Construction Machinery Utilizing Satellite Communication
Oct 21, 2025 21:00 JST
Hitachi and OpenAI form strategic partnership centered on global AI data center expansion
Oct 21, 2025 20:06 JST
Indonesia's Legacy in the Global Vaccine Landscape: Bio Farma and DCVMN Strengthen Health Resilience through Global Partnership
Oct 21, 2025 16:45 JST
Olympus: "Feasibility study on the development of Japanese digitalized endoscopy infection control systems in India" Selected for METI's FY2024 Supplementary "Global South Future-Oriented Co-Creation Subsidy Program (Small-Scale Demonstration / Feasibility Study Project)"
Oct 21, 2025 11:00 JST
MHI Thermal Systems Air-Conditioners for the Australian Market Recognized with Prestigious Awards
Oct 17, 2025 23:37 JST
SEKISUI CHEMICAL, Fujitsu, and SAP Japan announce comprehensive modernization of management platform to drive data-driven approach
Oct 17, 2025 23:00 JST
TransNusa to Launch Bali - Singapore Scheduled Flight on November 17
Oct 17, 2025 16:58 JST
MHIEC Receives Contract for Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Kanazawa
Oct 16, 2025 23:57 JST
Overview of Honda Exhibits at Japan Mobility Show 2025
Oct 16, 2025 23:20 JST
DENSO to Exhibit at JAPAN MOBILITY SHOW 2025
Oct 16, 2025 22:53 JST
Fujitsu and IISc launch joint research on advanced AI technologies to accelerate new material development and resolve societal challenges
Oct 16, 2025 21:55 JST
More Latest Release >>